Concepedia

Treatment of Mpox with Suspected Tecovirimat Resistance in Immunocompromised Patient, United States, 2022

Caitlin A. Contag, Leah Mische, Isabel Fong, Abraar Karan, Akanksha Vaidya, David W. McCormick, William A. Bower, Jill K. Hacker, Kelly Johnson, Perla SanJuan,

Emerging infectious diseases · 2023 · 19 citations · 7 references

DOI Full text

Open access

Concepts

Life SciencesInfectious DiseasesMicrobiologyAntimicrobial PharmacotherapyAntimicrobial ResistanceMedical MicrobiologyAntiviral Drug ResistanceAntiviral ResistanceAntiviral TherapyDefinitive Antimicrobial TherapyImmunocompromised Host InfectionsViral InfectionsAntiviral Resistance In Persistent InfectionDrug Resistance ManagementImmunocompromised Host Infection TreatmentImmunocompromised Host Management

Abstract

Reports of tecovirimat-resistant mpox have emerged after widespread use of antiviral therapy during the 2022 mpox outbreak. Optimal management of patients with persistent infection with or without suspected resistance is yet to be established. We report a successfully treated case of severe mpox in California, USA, that had suspected tecovirimat resistance.